Loading...

Vanda Pharmaceuticals

Nasdaq:VNDA
Snowflake Description

Flawless balance sheet with reasonable growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
VNDA
Nasdaq
$877M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The last earnings update was 61 days ago. More info.


Add to Portfolio Compare Print
  • Vanda Pharmaceuticals has significant price volatility in the past 3 months.
VNDA Share Price and Events
7 Day Returns
-5.8%
NasdaqGM:VNDA
-5.8%
US Biotechs
-0.3%
US Market
1 Year Returns
12.1%
NasdaqGM:VNDA
-3.1%
US Biotechs
7%
US Market
VNDA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Vanda Pharmaceuticals (VNDA) -5.8% -5.3% -46.4% 12.1% 76.4% 27.7%
US Biotechs -5.8% -7.4% -5.4% -3.1% -2.4% 16.7%
US Market -0.3% 2.2% 8.5% 7% 37.7% 46.8%
1 Year Return vs Industry and Market
  • VNDA outperformed the Biotechs industry which returned -3.1% over the past year.
  • VNDA outperformed the Market in United States of America which returned 7% over the past year.
Price Volatility
VNDA
Industry
5yr Volatility vs Market
Related Companies

VNDA Value

 Is Vanda Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Vanda Pharmaceuticals to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Vanda Pharmaceuticals.

NasdaqGM:VNDA Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 5 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 10.5%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGM:VNDA
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.446 (1 + (1- 21%) (0%))
1.299
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.3
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.299 * 5.96%)
10.47%

Discounted Cash Flow Calculation for NasdaqGM:VNDA using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Vanda Pharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NasdaqGM:VNDA DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 10.47%)
2019 11.26 Est @ 63.74% 10.19
2020 16.38 Est @ 45.44% 13.42
2021 21.72 Est @ 32.63% 16.11
2022 26.86 Est @ 23.66% 18.03
2023 31.53 Est @ 17.38% 19.16
2024 35.62 Est @ 12.98% 19.60
2025 39.15 Est @ 9.91% 19.50
2026 42.19 Est @ 7.75% 19.02
2027 44.82 Est @ 6.25% 18.29
2028 47.15 Est @ 5.19% 17.42
Present value of next 10 years cash flows $170.74
NasdaqGM:VNDA DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $47.15 × (1 + 2.73%) ÷ (10.47% – 2.73%)
$625.59
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $625.59 ÷ (1 + 10.47%)10
$231.06
NasdaqGM:VNDA Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $170.74 + $231.06
$401.80
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $401.80 / 52.64
$7.63
NasdaqGM:VNDA Discount to Share Price
Calculation Result
Value per share (USD) From above. $7.63
Current discount Discount to share price of $16.65
= -1 x ($16.65 - $7.63) / $7.63
-118.1%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Vanda Pharmaceuticals is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Vanda Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Vanda Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:VNDA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $0.50
NasdaqGM:VNDA Share Price ** NasdaqGM (2019-04-18) in USD $16.65
United States of America Biotechs Industry PE Ratio Median Figure of 35 Publicly-Listed Biotechs Companies 19.22x
United States of America Market PE Ratio Median Figure of 3,081 Publicly-Listed Companies 18.17x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Vanda Pharmaceuticals.

NasdaqGM:VNDA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:VNDA Share Price ÷ EPS (both in USD)

= 16.65 ÷ 0.50

33.59x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Vanda Pharmaceuticals is overvalued based on earnings compared to the US Biotechs industry average.
  • Vanda Pharmaceuticals is overvalued based on earnings compared to the United States of America market.
Price based on expected Growth
Does Vanda Pharmaceuticals's expected growth come at a high price?
Raw Data
NasdaqGM:VNDA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 33.59x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
27.2%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 28 Publicly-Listed Biotechs Companies 1.77x
United States of America Market PEG Ratio Median Figure of 2,109 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

NasdaqGM:VNDA PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 33.59x ÷ 27.2%

1.24x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Vanda Pharmaceuticals is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Vanda Pharmaceuticals's assets?
Raw Data
NasdaqGM:VNDA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $5.25
NasdaqGM:VNDA Share Price * NasdaqGM (2019-04-18) in USD $16.65
United States of America Biotechs Industry PB Ratio Median Figure of 416 Publicly-Listed Biotechs Companies 3.26x
United States of America Market PB Ratio Median Figure of 5,182 Publicly-Listed Companies 1.91x
NasdaqGM:VNDA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:VNDA Share Price ÷ Book Value per Share (both in USD)

= 16.65 ÷ 5.25

3.17x

* Primary Listing of Vanda Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Vanda Pharmaceuticals is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Vanda Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Vanda Pharmaceuticals has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

VNDA Future Performance

 How is Vanda Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
27.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Vanda Pharmaceuticals expected to grow at an attractive rate?
  • Vanda Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Vanda Pharmaceuticals's earnings growth is expected to exceed the United States of America market average.
  • Vanda Pharmaceuticals's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:VNDA Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:VNDA Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 27.2%
NasdaqGM:VNDA Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 12.3%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.5%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.1%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.4%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:VNDA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:VNDA Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 362 183 114 2
2022-12-31 328 118 77 2
2021-12-31 289 61 46 2
2020-12-31 273 46 63 4
2019-12-31 222 45 28 5
NasdaqGM:VNDA Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 193 30 25
2018-09-30 184 18 13
2018-06-30 177 12 1
2018-03-31 171 5 -5
2017-12-31 165 -2 -16
2017-09-30 159 -7 -14
2017-06-30 156 -8 -10
2017-03-31 150 -9 -13
2016-12-31 146 -8 -18
2016-09-30 140 -7 -32
2016-06-30 129 -13 -41
2016-03-31 121 2 -42

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Vanda Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • Vanda Pharmaceuticals's revenue is expected to grow by 12.3% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:VNDA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Vanda Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:VNDA Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 1.77 1.93 1.61 2.00
2022-12-31 1.25 1.36 1.13 2.00
2021-12-31 0.76 0.79 0.72 2.00
2020-12-31 0.51 1.69 -0.53 4.00
2019-12-31 0.19 0.62 -0.12 5.00
NasdaqGM:VNDA Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 0.50
2018-09-30 0.27
2018-06-30 0.03
2018-03-31 -0.11
2017-12-31 -0.35
2017-09-30 -0.32
2017-06-30 -0.23
2017-03-31 -0.30
2016-12-31 -0.41
2016-09-30 -0.75
2016-06-30 -0.96
2016-03-31 -0.99

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Vanda Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Vanda Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Vanda Pharmaceuticals has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

VNDA Past Performance

  How has Vanda Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Vanda Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Vanda Pharmaceuticals's year on year earnings growth rate has been positive over the past 5 years.
  • Vanda Pharmaceuticals has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
  • Vanda Pharmaceuticals has become profitable in the last year making it difficult to compare the US Biotechs industry average.
Earnings and Revenue History
Vanda Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Vanda Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:VNDA Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 193.12 25.21 105.75 43.59
2018-09-30 184.35 13.01 111.88 40.83
2018-06-30 176.55 1.29 116.96 39.61
2018-03-31 171.26 -4.86 120.37 37.40
2017-12-31 165.08 -15.57 123.84 38.55
2017-09-30 159.05 -14.33 116.70 36.01
2017-06-30 156.20 -10.21 107.48 33.12
2017-03-31 150.17 -13.30 100.79 32.18
2016-12-31 146.02 -18.01 99.79 29.16
2016-09-30 139.62 -32.20 104.76 30.29
2016-06-30 129.48 -41.23 101.31 32.97
2016-03-31 121.04 -42.00 95.02 32.22
2015-12-31 109.93 -39.87 84.53 29.15
2015-09-30 93.45 44.65 72.97 25.15
2015-06-30 79.88 52.69 65.80 18.88
2015-03-31 63.16 36.50 75.56 16.45
2014-12-31 50.16 20.19 84.64 19.23
2014-09-30 43.57 -57.28 77.25 20.75
2014-06-30 37.50 -61.26 71.70 25.07
2014-03-31 34.95 -43.07 48.82 27.65
2013-12-31 33.88 -21.06 25.08 28.50
2013-09-30 33.02 -19.68 17.84 33.39
2013-06-30 32.60 -19.60 15.36 35.41
2013-03-31 32.65 -24.22 14.81 40.70
2012-12-31 32.73 -28.62 14.52 45.76
2012-09-30 33.18 -26.82 15.53 37.87
2012-06-30 32.86 -24.57 15.26 35.72

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Vanda Pharmaceuticals has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Vanda Pharmaceuticals used its assets less efficiently than the US Biotechs industry average last year based on Return on Assets.
  • Vanda Pharmaceuticals has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).
X
Past performance checks
We assess Vanda Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Vanda Pharmaceuticals has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

VNDA Health

 How is Vanda Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Vanda Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Vanda Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Vanda Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Vanda Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Vanda Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Vanda Pharmaceuticals Company Filings, last reported 3 months ago.

NasdaqGM:VNDA Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 275.42 0.00 257.36
2018-09-30 261.42 0.00 240.58
2018-06-30 251.27 0.00 231.22
2018-03-31 241.14 0.00 248.83
2017-12-31 131.39 0.00 143.41
2017-09-30 130.47 0.00 139.88
2017-06-30 131.42 0.00 137.12
2017-03-31 128.14 0.00 137.76
2016-12-31 131.33 0.00 141.34
2016-09-30 129.17 0.00 142.58
2016-06-30 121.61 0.00 135.99
2016-03-31 123.01 0.00 138.33
2015-12-31 133.03 0.00 143.18
2015-09-30 145.94 0.00 144.32
2015-06-30 149.75 0.00 146.64
2015-03-31 152.47 0.00 134.33
2014-12-31 160.82 0.00 129.82
2014-09-30 1.06 0.00 56.09
2014-06-30 0.89 0.00 63.59
2014-03-31 20.98 0.00 100.40
2013-12-31 44.12 0.00 130.35
2013-09-30 50.00 0.00 142.17
2013-06-30 5.03 0.00 103.63
2013-03-31 6.48 0.00 110.93
2012-12-31 9.91 0.00 120.40
2012-09-30 15.35 0.00 134.40
2012-06-30 20.08 0.00 144.70
  • Vanda Pharmaceuticals has no debt.
  • Vanda Pharmaceuticals has not taken on any debt in the past 5 years.
  • Vanda Pharmaceuticals has no debt, it does not need to be covered by operating cash flow.
  • Vanda Pharmaceuticals has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess Vanda Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Vanda Pharmaceuticals has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

VNDA Dividends

 What is Vanda Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Vanda Pharmaceuticals dividends. Estimated to be 0% next year.
If you bought $2,000 of Vanda Pharmaceuticals shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Vanda Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Vanda Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:VNDA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 20 Stocks 2.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2009 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:VNDA Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Vanda Pharmaceuticals has not reported any payouts.
  • Unable to verify if Vanda Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Vanda Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Vanda Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Vanda Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Vanda Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Vanda Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Vanda Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

VNDA Management

 What is the CEO of Vanda Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mihael Polymeropoulos
COMPENSATION $3,797,395
AGE 58
TENURE AS CEO 15.9 years
CEO Bio

Dr. Mihael H. Polymeropoulos, M.D. founded Vanda Pharmaceuticals, Inc. in 2003 and has been its Chief Executive Officer, President and Director since May, 2003. Dr. Polymeropoulos has also been the Chief Financial Officer at Vanda Pharmaceuticals, Inc. since August 6, 2010 and served as its Principal Accounting Officer since August 6, 2010. He served as Vice President and Head of the Pharmacogenetics Department at Novartis Pharmaceuticals Corporation (Maryland) from 1998 to 2003. He served as the Chief of the Gene Mapping Section, Laboratory of Genetic Disease Research, NHGRI from 1992 to 1998. Dr. Polymeropoulos is the co-founder of the Integrated Molecular Analysis of Genome Expression (IMAGE) Consortium. He has published extensively on the subject of human genetics. Dr. Polymeropoulos holds a degree in Medicine from the University of Patras.

CEO Compensation
  • Mihael's compensation has been consistent with company performance over the past year.
  • Mihael's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Vanda Pharmaceuticals management team in years:

6
Average Tenure
52
Average Age
  • The average tenure for the Vanda Pharmaceuticals management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Mihael Polymeropoulos

TITLE
Founder
COMPENSATION
$4M
AGE
58
TENURE
15.9 yrs

Jim Kelly

TITLE
Executive VP
COMPENSATION
$2M
AGE
52
TENURE
8.3 yrs

Gunther Birznieks

TITLE
Senior Vice President of Business Development
COMPENSATION
$2M
AGE
49
TENURE
2.1 yrs

Gian Reverberi

TITLE
Senior VP & Chief Commercial Officer
COMPENSATION
$2M
AGE
52
TENURE
3.6 yrs

Tim Williams

TITLE
Senior VP
TENURE
0.7 yrs

Deepak Phadke

TITLE
Vice President of Manufacturing
COMPENSATION
$343K
AGE
68
TENURE
13.7 yrs
Board of Directors Tenure

Average tenure and age of the Vanda Pharmaceuticals board of directors in years:

9
Average Tenure
58
Average Age
  • The tenure for the Vanda Pharmaceuticals board of directors is about average.
Board of Directors

Tom Watkins

TITLE
Chairman of the Board
COMPENSATION
$210K
AGE
65
TENURE
5.1 yrs

Mihael Polymeropoulos

TITLE
Founder
COMPENSATION
$4M
AGE
58
TENURE
15.9 yrs

Richard Dugan

TITLE
Independent Director
COMPENSATION
$201K
AGE
76
TENURE
13.3 yrs

Vinnie, Vin Milano

TITLE
Independent Director
COMPENSATION
$204K
AGE
54
TENURE
9 yrs

Mike Cola

TITLE
Independent Director
COMPENSATION
$191K
AGE
58
TENURE
6.8 yrs
Who owns this company?
Recent Insider Trading
  • Vanda Pharmaceuticals insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
04. Mar 19 Sell James Kelly Individual 01. Mar 19 04. Mar 19 -13,727 $20.15 $-274,233
04. Mar 19 Sell Gian Reverberi Individual 01. Mar 19 04. Mar 19 -881 $20.17 $-17,655
04. Mar 19 Sell Mihael Polymeropoulos Individual 01. Mar 19 04. Mar 19 -44,666 $20.22 $-872,226
04. Mar 19 Sell Gunther Birznieks Individual 01. Mar 19 04. Mar 19 -12,529 $20.14 $-250,092
04. Jan 19 Sell Mihael Polymeropoulos Individual 02. Jan 19 03. Jan 19 -15,236 $26.93 $-401,663
04. Jan 19 Sell Gian Reverberi Individual 02. Jan 19 02. Jan 19 -1,130 $26.94 $-30,042
04. Jan 19 Sell James Kelly Individual 02. Jan 19 03. Jan 19 -6,061 $26.94 $-159,811
04. Jan 19 Sell Gunther Birznieks Individual 02. Jan 19 03. Jan 19 -6,061 $26.95 $-159,810
X
Management checks
We assess Vanda Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Vanda Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

VNDA News

Simply Wall St News

With A 9.2% Return On Equity, Is Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) A Quality Stock?

By way of learning-by-doing, we'll look at ROE to gain a better understanding of Vanda Pharmaceuticals Inc. … That means that for every $1 worth of shareholders' equity, it generated $0.092 in profit. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA): Will The Growth Last?

Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) most recent earnings update in December 2018 … finally turned profitable … negative earnings

Simply Wall St -

Did Business Growth Power Vanda Pharmaceuticals's Share Price Gain of 146%?

(NASDAQ:VNDA) shareholders are probably rather concerned to see the share price fall 30% over the last three months. … So the recent fall in the share price should be viewed in that context. … One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.

Simply Wall St -

Does Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) CEO Pay Matter?

Mihael Polymeropoulos became the CEO of Vanda Pharmaceuticals Inc. … This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … How Does Mihael Polymeropoulos's Compensation Compare With Similar Sized Companies?

Simply Wall St -

What Investors Should Know About Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) Financial Strength

However, it also faces higher cost of capital given interest cost is generally lower than equity. … Does VNDA's growth rate justify its decision for financial flexibility over lower cost of capital … Debt capital generally has lower cost of capital compared to equity funding.

Simply Wall St -

Does Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Have A Volatile Share Price?

Every stock in the market is exposed to this volatility, which is linked to the fact that stocks prices are correlated in an efficient market. … Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … Any stock with a beta of greater than one is considered more volatile than the market, while those with a beta below one are either less volatile or poorly correlated with the market.

Simply Wall St -

A Closer Look At Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) Uninspiring ROE

With that in mind, this article will work through how we can use Return On Equity (ROE) to better understand a business. … Our data shows Vanda Pharmaceuticals has a return on equity of 5.0% for the last year. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

Is Vanda Pharmaceuticals Inc (NASDAQ:VNDA) Expensive For A Reason? A Look At The Intrinsic Value

Today I will be providing a simple run through of a valuation method used to estimate the attractiveness of Vanda Pharmaceuticals Inc (NASDAQ:VNDA) as an investment opportunity. … by estimating the company's future cash flows and discounting them to their present value. … If you are reading this and its not November 2018 then I highly recommend you check out the latest calculation for Vanda Pharmaceuticals by following the link below

Simply Wall St -

Is Vanda Pharmaceuticals Inc (NASDAQ:VNDA) A Financially Sound Company?

The direct benefit for Vanda Pharmaceuticals Inc (NASDAQ:VNDA), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. … However, the trade-off is VNDA will have to adhere to stricter debt covenants and have less financial flexibility. … Does VNDA's growth rate justify its decision for financial flexibility over lower cost of capital.

Simply Wall St -

Vanda Pharmaceuticals Inc (NASDAQ:VNDA): Has Recent Earnings Growth Beaten Long-Term Trend?

When Vanda Pharmaceuticals Inc (NASDAQ:VNDA) released its most recent earnings update (31 March 2018), I wanted to understand how these figures stacked up against its past performance. … The two benchmarks I used were Vanda Pharmaceuticals's average earnings over the past couple of years, and its industry performance. … VNDA is loss-making, with the most recent trailing twelve-month earnings of -US$4.86m (from 31 March 2018), which compared to last year has become

Simply Wall St -

VNDA Company Info

Description

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company’s marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia. Its products also include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; VTR-297, a small molecule histone deacetylase inhibitor, which is in clinical development stage for the treatment of hematologic malignancies; and VQW-765, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. In addition, the company is developing cystic fibrosis transmembrane conductance regulator activators and inhibitors. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Details
Name: Vanda Pharmaceuticals Inc.
VNDA
Exchange: NasdaqGM
Founded: 2002
$876,501,854
52,642,754
Website: http://www.vandapharmaceuticals.com
Address: Vanda Pharmaceuticals Inc.
2200 Pennsylvania Avenue NW,
Suite 300E,
Washington,
District Of Columbia, 20037,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM VNDA Common Stock Nasdaq Global Market US USD 12. Apr 2006
DB VM4 Common Stock Deutsche Boerse AG DE EUR 12. Apr 2006
LSE 0LKB Common Stock London Stock Exchange GB USD 12. Apr 2006
Number of employees
Current staff
Staff numbers
270
Vanda Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/21 00:01
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/03/12
Last earnings filing: 2019/02/19
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.